US FDA expected to soon authorise Pfizer-BioNTech’s Covid-19 booster for younger kids

WASHINGTON (NYTIMES) – The US Food and Drug Administration (FDA) is expected as early as Tuesday (March 17) to authorise a booster shot of the Pfizer-BioNTech vaccine for children 5 to 11, according to multiple people familiar with the plan.

That would make those children the youngest Americans eligible for the additional shot.  

The companies announced a month ago that the extra shot significantly increased the level of neutralising antibodies against both the original version of the virus and the Omicron variant in a small clinical trial of 140 children.

Other research has suggested that the protection against infection provided by two Pfizer shots wanes within just a few weeks for 5- to 11-year-olds, underscoring the need for a booster dose.  

A meeting of outside vaccine experts on an advisory committee to the Centres for Disease Control and Prevention (CDC) has been scheduled for Thursday.

CDC Director Dr Rochelle Walensky is then expected to issue her own recommendation on the shot.  

There are more than 28 million children ages 5-11, making up nearly 40 per cent of Americans younger than age 18.

But given that these children have the lowest coronavirus vaccination rate of all eligible Americans, public health experts are not expecting a rush for the booster.

Although they have been eligible for Covid shots since November, only 28.8 per cent of children in this age group have received two doses. Another 6 per cent or so have received one shot.  

There is no coronavirus vaccine available yet for children younger than 5, but data is rolling in from both Moderna and Pfizer on their clinical trial results and regulators are expected to decide if the proposed regimens pass muster within about a month.  

Americans 12 and older are eligible for an initial booster at least five months after their second shot, and about 30 million people 50 or older, as well as many people with immune deficiencies, are eligible for a second at least four months after that.  

Several hundred children ages 5-11 have died of Covid, according to the CDC, but many parents have hesitated to vaccinate their children, apparently because the risk of severe illness is comparatively low.

The lowest rates of vaccination have been in southern states.  

In the Pfizer-BioNTech clinical trial, children showed a sixfold increase in antibody levels against the original version of the virus one month after receiving the booster, compared with one month after receiving a second dose.

The third dose was given about six months after the second shot.

Source link

Denial of responsibility! planetcirculate is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.